Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CEN Biotech, Inc. (CENBF)
USD0.00
+0.00 (+0.00%)
CA OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
3295 Quality Way N8T 3R9
Windsor, ON, CA
Windsor, ON, CA
CEO
Brian S. Payne
Website
cenbiotechinc.com
IPO
2020-05-04
CIK 1653821 ISIN CA15130L1040
Description
CEN Biotech, Inc. specializes in the creation, production, and ongoing development of both LED lighting technology and goods made from hemp. The company's future plans include cultivating hemp for use across various sectors, including industrial, medical, and food applications. Furthermore, it provides services in the areas of digital marketing and website development. The firm was founded in 2013 and has its headquarters in Windsor, Canada.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
203
Beta
-8.35
Float Shares
32.48M
Free Float %
49.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.54% | -99.98% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Unlevered)
0.78
+780,045.3%
DCF (Levered)
0.26
+259,183.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-9.88
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+57.5% ★ Q3'23: -52.0% (vs Q3'22)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+94.8% ★ Q3'23: +216.3% (vs Q3'22)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-133.8% Q3'23: +608.3% (vs Q3'22)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-127.9% Q3'23: +628.4% (vs Q3'22)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-44.2% Q3'23: +80.7% (vs Q3'22)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+52.6% Q3'23: +2.0% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-6.76× Q3'23: 3.04× (vs Q3'22)
Valuation Multiples
From
To
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-1.31M
OE per share TTM
-0.02
Owner's Yield
-20,134.00%
Maintenance CapEx ratio
52.47%
Maint CapEx / Avg PPE
226.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
2.50M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+2,500,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-06 | Purdy Rick Leigh | Director / Officer | A-Award | A | Common Stock | 2,500,000 | 0.00 | — | 2,809,470 | — | ↗ |
| 2021-07-09 | Lehoux Lawrence | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 3,030,000 | — | ↗ |
| 2021-06-25 | Tarrabain Alex | Director / Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 2,775,942 | — | ↗ |
| 2021-06-16 | Tarrabain Alex | Director / Officer | J-Other | A | Common Stock | 3,000 | 0.00 | — | 2,775,942 | — | ↗ |
| 2021-05-16 | Tarrabain Alex | Director / Officer | J-Other | A | Common Stock | 3,000 | 0.00 | — | 1,772,942 | — | ↗ |
| 2021-04-19 | Thomas Jeffery Allen | Director | — | D | Common Stock | 0 | 0.00 | — | 42,857 | — | ↗ |
| 2021-04-19 | Purdy Rick Leigh | Director | — | D | Common Stock | 0 | 0.00 | — | 215,720 | — | ↗ |
| 2021-04-19 | Byrne Joseph A. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 1,364,894 | — | ↗ |
| 2021-04-10 | Tarrabain Alex | Director / Officer | C-Conversion | A | Common Stock | 30,000 | 1.60 | 48.0K | 1,772,942 | — | ↗ |
| 2021-04-02 | Tarrabain Alex | Director / Officer | A-Award | A | Common Stock | 300,000 | 0.00 | — | 1,772,942 | — | ↗ |
| 2021-04-02 | Strilchuck Donald | Director | A-Award | A | Common Stock | 341,250 | 0.00 | — | 1,361,250 | — | ↗ |
| 2021-04-02 | Saadikh Usamakh | Director | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,020,000 | — | ↗ |
| 2021-04-02 | Payne Brian | Director / Officer | A-Award | A | Common Stock | 1,435,000 | 0.00 | — | 2,209,285 | — | ↗ |
| 2021-04-02 | Ferris Ameen | Director / Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,020,000 | — | ↗ |
| 2021-04-02 | Chaaban Bahige B. | Director / Officer / 10% Owner | A-Award | A | Common Stock | 3,106,122 | 0.00 | — | 11,002,432 | — | ↗ |
| 2021-04-02 | Boswell Richard | Director / Officer / 10% Owner | A-Award | A | Common Stock | 2,185,679 | 0.00 | — | 6,000,000 | — | ↗ |
| 2021-04-02 | Aubrey de Lavenu Harold Andre | Director | A-Award | A | Common Stock | 1,041,250 | 0.00 | — | 1,623,551 | — | ↗ |
| 2021-01-27 | Boswell Richard | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 6,250 | 0.80 | 5.0K | 6,000,000 | — | ↗ |
| 2021-01-26 | Boswell Richard | Director / Officer / 10% Owner | S-Sale | D | Common Stock | 37,500 | 0.40 | 15.0K | 6,000,000 | — | ↗ |
| 2020-12-31 | Tarrabain Alex | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-31 | Boswell Richard | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-31 | Tarrabain Alex | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-31 | Chaaban Bahige B. | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-31 | Byrne Joseph A. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-12-31 | Boswell Richard | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-31 | Tarrabain Alex | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-31 | Byrne Joseph A. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-11-15 | Aubrey de Lavenu Harold Andre | Director | J-Other | D | Convertible note | 171,632 | 1.60 | 274.6K | 548,980 | — | ↗ |
| 2018-06-07 | Saadikh Usamakh | Director | — | D | Common Stock | 0 | 0.00 | — | 20,000 | — | ↗ |
| 2018-01-15 | Purdy Rick Leigh | Director | — | D | Convertible Note | 31,250 | 1.60 | 50.0K | 0 | — | ↗ |
| 2017-12-31 | Tarrabain Alex | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-31 | Strilchuck Donald | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-31 | Payne Brian | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-31 | Ferris Ameen | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-31 | Chaaban Bahige B. | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-31 | Byrne Joseph A. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-31 | Boswell Richard | Director / Officer / 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-31 | Aubrey de Lavenu Harold Andre | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-12 | Tarrabain Alex | Director | — | D | Common Stock | 0 | 0.00 | — | 49,942 | — | ↗ |
| 2017-07-12 | Strilchuck Donald | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-12 | Payne Brian | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 4,285 | — | ↗ |
| 2017-07-12 | Ferris Ameen | Director | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-07-12 | Byrne Joseph A. | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 12,894 | — | ↗ |
| 2017-07-12 | Boswell Richard | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,571 | — | ↗ |
| 2017-07-12 | Aubrey de Lavenu Harold Andre | Director | — | D | Common Stock | 0 | 0.00 | — | 13,321 | — | ↗ |
| 2017-02-19 | Aubrey de Lavenu Harold Andre | Director | — | D | Convertible Note | 312,500 | 1.60 | 500.0K | 0 | — | ↗ |
| 2017-02-09 | Aubrey de Lavenu Harold Andre | Director | — | D | Convertible Note | 312,500 | 1.60 | 500.0K | 0 | — | ↗ |
| 2016-10-26 | Tarrabain Alex | Director | — | D | Convertible Note | 30,000 | 0.00 | — | 0 | — | ↗ |
| 2016-08-17 | Byrne Joseph A. | Director / Officer | — | D | Common Stock | 76,123 | 1.60 | 121.8K | 0 | — | ↗ |
| 2016-02-29 | Chaaban Bahige B. | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 144,793 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-315.5K
Shares Outstanding
65.26M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Harold Andre Aubrey De Lavenu | Vice President & Independent Director | 31.3K | male |
| Brian S. Payne | Chief Executive Officer, Chief Financial Officer, Vice President, Secretary & Chairman of the Board | 31.2K | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CENBF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
